vs
拉夫劳伦（RL）与福泰制药（VRTX）财务数据对比。点击上方公司名可切换其他公司
福泰制药的季度营收约是拉夫劳伦的1.3倍（$3.2B vs $2.4B），福泰制药净利率更高（37.3% vs 15.0%，领先22.3%），拉夫劳伦同比增速更快（12.2% vs 9.5%），拉夫劳伦自由现金流更多（$704.0M vs $348.6M），过去两年拉夫劳伦的营收复合增速更高（23.9% vs 8.9%）
拉夫劳伦是源自美国的跨国时尚巨头，旗下同名高端时尚品牌风靡全球，企业规模达数十亿美元。品牌创始人拉夫劳伦于2015年9月卸任首席执行官，仍留任执行董事长兼首席创意官，主导品牌创意与整体发展方向。
福泰制药是总部位于美国马萨诸塞州波士顿的生物制药企业，是全球首批明确采用理性药物设计策略、而非组合化学方法开发药物的生物技术公司之一。除波士顿总部外，公司还在加州圣迭戈、英国牛津郡米尔顿公园设有三处研发中心。
RL vs VRTX — 直观对比
营收规模更大
VRTX
是对方的1.3倍
$2.4B
营收增速更快
RL
高出2.7%
9.5%
净利率更高
VRTX
高出22.3%
15.0%
自由现金流更多
RL
多$355.4M
$348.6M
两年增速更快
RL
近两年复合增速
8.9%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.4B | $3.2B |
| 净利润 | $361.6M | $1.2B |
| 毛利率 | 69.9% | 85.4% |
| 营业利润率 | 19.6% | 37.8% |
| 净利率 | 15.0% | 37.3% |
| 营收同比 | 12.2% | 9.5% |
| 净利润同比 | 21.6% | 30.5% |
| 每股收益（稀释后） | $5.82 | $4.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RLVRTX
| Q4 25 | $2.4B | $3.2B | ||
| Q3 25 | $2.0B | $3.1B | ||
| Q2 25 | $1.7B | $3.0B | ||
| Q1 25 | $1.7B | $2.8B | ||
| Q4 24 | $2.1B | $2.9B | ||
| Q3 24 | $1.7B | $2.8B | ||
| Q2 24 | $1.5B | $2.6B | ||
| Q1 24 | $1.6B | $2.7B |
净利润RLVRTX
| Q4 25 | $361.6M | $1.2B | ||
| Q3 25 | $207.5M | $1.1B | ||
| Q2 25 | $220.4M | $1.0B | ||
| Q1 25 | $129.0M | $646.3M | ||
| Q4 24 | $297.4M | $913.0M | ||
| Q3 24 | $147.9M | $1.0B | ||
| Q2 24 | $168.6M | $-3.6B | ||
| Q1 24 | $90.7M | $1.1B |
毛利率RLVRTX
| Q4 25 | 69.9% | 85.4% | ||
| Q3 25 | 68.0% | 86.5% | ||
| Q2 25 | 72.3% | 86.3% | ||
| Q1 25 | 68.7% | 86.9% | ||
| Q4 24 | 68.4% | 85.5% | ||
| Q3 24 | 67.0% | 85.8% | ||
| Q2 24 | 70.5% | 85.9% | ||
| Q1 24 | 66.6% | 87.3% |
营业利润率RLVRTX
| Q4 25 | 19.6% | 37.8% | ||
| Q3 25 | 12.2% | 38.6% | ||
| Q2 25 | 15.9% | 38.8% | ||
| Q1 25 | 9.1% | 22.7% | ||
| Q4 24 | 18.2% | 35.2% | ||
| Q3 24 | 10.4% | 40.3% | ||
| Q2 24 | 13.8% | -132.9% | ||
| Q1 24 | 6.9% | 42.4% |
净利率RLVRTX
| Q4 25 | 15.0% | 37.3% | ||
| Q3 25 | 10.3% | 35.2% | ||
| Q2 25 | 12.8% | 34.8% | ||
| Q1 25 | 7.6% | 23.3% | ||
| Q4 24 | 13.9% | 31.4% | ||
| Q3 24 | 8.6% | 37.7% | ||
| Q2 24 | 11.1% | -135.8% | ||
| Q1 24 | 5.8% | 40.9% |
每股收益（稀释后）RLVRTX
| Q4 25 | $5.82 | $4.64 | ||
| Q3 25 | $3.32 | $4.20 | ||
| Q2 25 | $3.52 | $3.99 | ||
| Q1 25 | $2.03 | $2.49 | ||
| Q4 24 | $4.66 | $3.62 | ||
| Q3 24 | $2.31 | $4.01 | ||
| Q2 24 | $2.61 | $-13.92 | ||
| Q1 24 | $1.37 | $4.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.3B | $6.6B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $18.7B |
| 总资产 | $7.8B | $25.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RLVRTX
| Q4 25 | $2.3B | $6.6B | ||
| Q3 25 | $1.6B | $6.3B | ||
| Q2 25 | $2.3B | $6.4B | ||
| Q1 25 | $2.1B | $6.2B | ||
| Q4 24 | $2.1B | $6.1B | ||
| Q3 24 | $1.7B | $6.5B | ||
| Q2 24 | $1.8B | $5.8B | ||
| Q1 24 | $1.8B | $10.2B |
股东权益RLVRTX
| Q4 25 | $2.9B | $18.7B | ||
| Q3 25 | $2.6B | $17.3B | ||
| Q2 25 | $2.5B | $17.2B | ||
| Q1 25 | $2.6B | $16.5B | ||
| Q4 24 | $2.5B | $16.4B | ||
| Q3 24 | $2.4B | $15.6B | ||
| Q2 24 | $2.4B | $14.8B | ||
| Q1 24 | $2.5B | $18.5B |
总资产RLVRTX
| Q4 25 | $7.8B | $25.6B | ||
| Q3 25 | $7.3B | $24.9B | ||
| Q2 25 | $7.8B | $24.0B | ||
| Q1 25 | $7.0B | $22.9B | ||
| Q4 24 | $7.1B | $22.5B | ||
| Q3 24 | $6.8B | $22.2B | ||
| Q2 24 | $6.6B | $20.1B | ||
| Q1 24 | $6.6B | $23.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $779.6M | $498.0M |
| 自由现金流经营现金流 - 资本支出 | $704.0M | $348.6M |
| 自由现金流率自由现金流/营收 | 29.3% | 10.9% |
| 资本支出强度资本支出/营收 | 3.1% | 4.7% |
| 现金转化率经营现金流/净利润 | 2.16× | 0.42× |
| 过去12个月自由现金流最近4个季度 | $694.5M | $3.2B |
8季度趋势，按日历期对齐
经营现金流RLVRTX
| Q4 25 | $779.6M | $498.0M | ||
| Q3 25 | $53.2M | $1.2B | ||
| Q2 25 | $176.1M | $1.1B | ||
| Q1 25 | $122.2M | $818.9M | ||
| Q4 24 | $738.4M | $584.6M | ||
| Q3 24 | $97.2M | $1.4B | ||
| Q2 24 | $277.3M | $-3.8B | ||
| Q1 24 | — | $1.3B |
自由现金流RLVRTX
| Q4 25 | $704.0M | $348.6M | ||
| Q3 25 | $-40.6M | $1.1B | ||
| Q2 25 | $-11.2M | $927.4M | ||
| Q1 25 | $42.3M | $778.2M | ||
| Q4 24 | $677.2M | $492.0M | ||
| Q3 24 | $55.5M | $1.3B | ||
| Q2 24 | $243.9M | $-3.8B | ||
| Q1 24 | — | $1.2B |
自由现金流率RLVRTX
| Q4 25 | 29.3% | 10.9% | ||
| Q3 25 | -2.0% | 37.0% | ||
| Q2 25 | -0.7% | 31.3% | ||
| Q1 25 | 2.5% | 28.1% | ||
| Q4 24 | 31.6% | 16.9% | ||
| Q3 24 | 3.2% | 47.0% | ||
| Q2 24 | 16.1% | -144.5% | ||
| Q1 24 | — | 46.0% |
资本支出强度RLVRTX
| Q4 25 | 3.1% | 4.7% | ||
| Q3 25 | 4.7% | 3.3% | ||
| Q2 25 | 10.9% | 4.9% | ||
| Q1 25 | 4.7% | 1.5% | ||
| Q4 24 | 2.9% | 3.2% | ||
| Q3 24 | 2.4% | 2.4% | ||
| Q2 24 | 2.2% | 2.6% | ||
| Q1 24 | — | 2.5% |
现金转化率RLVRTX
| Q4 25 | 2.16× | 0.42× | ||
| Q3 25 | 0.26× | 1.15× | ||
| Q2 25 | 0.80× | 1.04× | ||
| Q1 25 | 0.95× | 1.27× | ||
| Q4 24 | 2.48× | 0.64× | ||
| Q3 24 | 0.66× | 1.31× | ||
| Q2 24 | 1.64× | — | ||
| Q1 24 | — | 1.19× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RL
暂无分部数据
VRTX
| TRIKAFTAKAFTRIO | $2.6B | 81% |
| ALYFTREK | $380.1M | 12% |
| Manufactured Product Other | $237.4M | 7% |
